The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A phase 1/2 trial of Pembrolizumab in metastatic cancer and ovarian cancer, run by PMV Pharmaceuticals, Inc, now recruiting.
Overview
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is a phase 1/2 interventional study registered as NCT04585750 by PMV Pharmaceuticals, Inc, with 300 participants planned, started 2020-10-29 and due to reach its primary completion in 2026-12-15. Interventions recorded: rezatapopt, pembrolizumab. Conditions listed: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer.
- Trial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer.
- TrialA Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Shares Endometrial cancer, Ovarian cancer, Metastatic cancer (cancer that has spread), Colorectal cancer.
- TrialStudy of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Shares Endometrial cancer, Pembrolizumab, Metastatic cancer (cancer that has spread).
- PersonRobert S. Mannel
Shares Endometrial cancer, Ovarian cancer.
- PersonKaren H. Lu
Shares Endometrial cancer, Ovarian cancer.
- PersonMatthew A. Powell
Shares Endometrial cancer, Ovarian cancer.